For more than two decades, RaySearch Laboratories has created value by advancing cancer treatment through software innovation. We aim to keep you informed about our performance and other factors relevant to your assessment of RaySearch as an investment.
INVESTOR RELATIONS
Key figures (rolling 12m)
Latest press releases
Accuray and RaySearch agree to collaboration integrating RayStation software with Accuray platforms to accelerate Accuray’s online adaptive capabilities
Interim report second quarter 2026: Delayed USA orders weighed on second quarter
Strong order momentum in the USA at the start of the third quarter
Financial Calendar
The Share
ANNUAL REPORT 2025
2025 clearly demonstrated the strength and long-term potential of RaySearch. Despite macroeconomic uncertainty, we reached record net sales and achieved important clinical milestones. In the Annual Report, we share the year’s key highlights, financial performance, and sustainability efforts – and how our software continues to shape data-driven cancer care worldwide.
Subscribe
IR contact
- Carolina Haglund Strömlid
- Head of Investor Relations
- ir@raysearchlabs.com
- +46 (0)70 880 71 73